Kerry Segal is Senior Director of Business and Corporate Development of Terns Pharmaceuticals. Kerry is an experienced veteran of the pharmaceutical industry, with over 30-years of relevant experience and a proven record of success in business and corporate development. Kerry’s expertise involves multiple stages of business development, including negotiations and transactions, in-licensing, out-licensing, and M&A deals. Prior to joining Terns, Kerry held leadership roles at Impax Pharma, Valeant Pharma, Cephalon, and Johnson and Johnson.
Kerry holds a B.S. in accounting and an MBA, with a major in marketing, both from Temple University.